vs
Amphastar Pharmaceuticals, Inc.（AMPH）与GIBRALTAR INDUSTRIES, INC.（ROCK）财务数据对比。点击上方公司名可切换其他公司
GIBRALTAR INDUSTRIES, INC.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.2倍（$225.0M vs $183.1M），GIBRALTAR INDUSTRIES, INC.同比增速更快（24.9% vs -1.8%），GIBRALTAR INDUSTRIES, INC.自由现金流更多（$26.2M vs $24.6M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs -12.3%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
直布罗陀工业公司是专业建筑、基础设施及可再生能源产品制造商与分销商，主营通风系统、屋面配件、太阳能安装支架、园林景观产品等，主要服务北美地区住宅、商业建筑及清洁能源市场，专注提供创新可持续的客户解决方案。
AMPH vs ROCK — 直观对比
营收规模更大
ROCK
是对方的1.2倍
$183.1M
营收增速更快
ROCK
高出26.8%
-1.8%
自由现金流更多
ROCK
多$1.6M
$24.6M
两年增速更快
AMPH
近两年复合增速
-12.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $225.0M |
| 净利润 | $24.4M | — |
| 毛利率 | 46.8% | 25.3% |
| 营业利润率 | 19.4% | 7.9% |
| 净利率 | 13.3% | — |
| 营收同比 | -1.8% | 24.9% |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHROCK
| Q4 25 | $183.1M | $225.0M | ||
| Q3 25 | $191.8M | $310.9M | ||
| Q2 25 | $174.4M | $309.5M | ||
| Q1 25 | $170.5M | $290.0M | ||
| Q4 24 | $186.5M | $180.1M | ||
| Q3 24 | $191.2M | $277.1M | ||
| Q2 24 | $182.4M | $273.6M | ||
| Q1 24 | $171.8M | $292.5M |
净利润AMPHROCK
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-89.1M | ||
| Q2 25 | $31.0M | $26.0M | ||
| Q1 25 | $25.3M | $21.1M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $34.0M | ||
| Q2 24 | $37.9M | $32.2M | ||
| Q1 24 | $43.2M | $24.9M |
毛利率AMPHROCK
| Q4 25 | 46.8% | 25.3% | ||
| Q3 25 | 51.4% | 26.6% | ||
| Q2 25 | 49.6% | 28.4% | ||
| Q1 25 | 50.0% | 26.8% | ||
| Q4 24 | 46.5% | 29.0% | ||
| Q3 24 | 53.3% | 29.4% | ||
| Q2 24 | 52.2% | 30.5% | ||
| Q1 24 | 52.4% | 28.9% |
营业利润率AMPHROCK
| Q4 25 | 19.4% | 7.9% | ||
| Q3 25 | 13.2% | 12.8% | ||
| Q2 25 | 24.2% | 12.8% | ||
| Q1 25 | 21.9% | 8.8% | ||
| Q4 24 | 24.2% | 13.3% | ||
| Q3 24 | 29.8% | 15.6% | ||
| Q2 24 | 30.3% | 14.9% | ||
| Q1 24 | 27.9% | 10.8% |
净利率AMPHROCK
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -28.6% | ||
| Q2 25 | 17.8% | 8.4% | ||
| Q1 25 | 14.8% | 7.3% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 12.3% | ||
| Q2 24 | 20.8% | 11.8% | ||
| Q1 24 | 25.1% | 8.5% |
每股收益（稀释后）AMPHROCK
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | $-2.98 | ||
| Q2 25 | $0.64 | $0.87 | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | $1.11 | ||
| Q2 24 | $0.73 | $1.05 | ||
| Q1 24 | $0.81 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $115.7M |
| 总债务越低越好 | $608.7M | $0 |
| 股东权益账面价值 | $788.8M | $950.4M |
| 总资产 | $1.6B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资AMPHROCK
| Q4 25 | $282.8M | $115.7M | ||
| Q3 25 | $276.2M | $89.4M | ||
| Q2 25 | $231.8M | $43.3M | ||
| Q1 25 | $236.9M | $25.1M | ||
| Q4 24 | $221.6M | $269.5M | ||
| Q3 24 | $250.5M | $228.9M | ||
| Q2 24 | $217.8M | $179.1M | ||
| Q1 24 | $289.6M | $146.7M |
总债务AMPHROCK
| Q4 25 | $608.7M | $0 | ||
| Q3 25 | $608.6M | $0 | ||
| Q2 25 | $607.7M | $0 | ||
| Q1 25 | $603.9M | $0 | ||
| Q4 24 | $601.6M | $0 | ||
| Q3 24 | $596.4M | $0 | ||
| Q2 24 | $586.9M | $0 | ||
| Q1 24 | $594.0M | $0 |
股东权益AMPHROCK
| Q4 25 | $788.8M | $950.4M | ||
| Q3 25 | $776.7M | $951.8M | ||
| Q2 25 | $757.5M | $1.0B | ||
| Q1 25 | $751.3M | $1.0B | ||
| Q4 24 | $732.3M | $1.0B | ||
| Q3 24 | $727.7M | $1.0B | ||
| Q2 24 | $713.3M | $975.7M | ||
| Q1 24 | $672.4M | $940.2M |
总资产AMPHROCK
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.4B | ||
| Q2 24 | $1.5B | $1.4B | ||
| Q1 24 | $1.6B | $1.3B |
负债/权益比AMPHROCK
| Q4 25 | 0.77× | 0.00× | ||
| Q3 25 | 0.78× | 0.00× | ||
| Q2 25 | 0.80× | 0.00× | ||
| Q1 25 | 0.80× | 0.00× | ||
| Q4 24 | 0.82× | 0.00× | ||
| Q3 24 | 0.82× | 0.00× | ||
| Q2 24 | 0.82× | 0.00× | ||
| Q1 24 | 0.88× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $35.5M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $26.2M |
| 自由现金流率自由现金流/营收 | 13.4% | 11.7% |
| 资本支出强度资本支出/营收 | 4.5% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $120.6M |
8季度趋势，按日历期对齐
经营现金流AMPHROCK
| Q4 25 | $32.9M | $35.5M | ||
| Q3 25 | $52.6M | $73.0M | ||
| Q2 25 | $35.6M | $44.9M | ||
| Q1 25 | $35.1M | $13.7M | ||
| Q4 24 | $29.0M | $19.9M | ||
| Q3 24 | $60.0M | $64.7M | ||
| Q2 24 | $69.1M | $36.5M | ||
| Q1 24 | $55.3M | $53.2M |
自由现金流AMPHROCK
| Q4 25 | $24.6M | $26.2M | ||
| Q3 25 | $47.2M | $64.8M | ||
| Q2 25 | $25.0M | $27.3M | ||
| Q1 25 | $24.4M | $2.3M | ||
| Q4 24 | $16.6M | $14.1M | ||
| Q3 24 | $46.2M | $60.5M | ||
| Q2 24 | $63.1M | $33.5M | ||
| Q1 24 | $46.5M | $48.8M |
自由现金流率AMPHROCK
| Q4 25 | 13.4% | 11.7% | ||
| Q3 25 | 24.6% | 20.8% | ||
| Q2 25 | 14.3% | 8.8% | ||
| Q1 25 | 14.3% | 0.8% | ||
| Q4 24 | 8.9% | 7.8% | ||
| Q3 24 | 24.1% | 21.8% | ||
| Q2 24 | 34.6% | 12.2% | ||
| Q1 24 | 27.1% | 16.7% |
资本支出强度AMPHROCK
| Q4 25 | 4.5% | 4.1% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 6.1% | 5.7% | ||
| Q1 25 | 6.3% | 3.9% | ||
| Q4 24 | 6.7% | 3.3% | ||
| Q3 24 | 7.2% | 1.5% | ||
| Q2 24 | 3.3% | 1.1% | ||
| Q1 24 | 5.1% | 1.5% |
现金转化率AMPHROCK
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 1.73× | ||
| Q1 25 | 1.39× | 0.65× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 1.90× | ||
| Q2 24 | 1.82× | 1.13× | ||
| Q1 24 | 1.28× | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
